An interventional study of Anticoagulation and mechanical aspiration thrombectomy in Pulmonary Embolism Acute, sponsored by Penumbra Inc.. Completed at 22 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Penumbra Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Pulmonary Embolism with a site in United States — 34 open to participants now, 43 under way, 6 of them phase 3. Pulmonary Embolism · United States.
Among the 236 studies in Pulmonary Embolism with a site in United States, this one is the 108th largest by enrollment of the 166 interventional ones that give a count, is one of 15 that started in 2023, is one of 82 with no phase, and was the 195th registered.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
Browse Pulmonary Embolism studies →34 of the 236 studies in Pulmonary Embolism with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Bulgaria, Japan and 2 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 21+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Canada
Ages 18+
Angiodynamics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 38 · Phase 4 21
First in 1999; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is below the median of 174 across 430 interventional studies indexed under Pulmonary Embolism.
Median enrollment 142 across the 166 interventional studies, 286 across the 68 observational. Of the 169 that completed or were terminated, 76 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 236 have an industry lead sponsor. The 10 most frequent:
Penumbra Inc. is the lead sponsor of 33 studies on the registry; 4 are open to participants now.
Penumbra Inc. has 3 studies filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
17 of the studies in Pulmonary Embolism with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05591118Phase 3NYU Langone HealthPulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy | 2027-03-29 |
| NCT07213778Phase 3Regeneron PharmaceuticalsREGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | 2027-05-17 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT04798261Penumbra Inc.Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 236 studies in Pulmonary Embolism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to evaluate the safety and efficacy of treatment with anticoagulation alone versus anticoagulation and mechanical aspiration thrombectomy with the Indigo Aspiration System for the treatment of intermediate-high risk acute pulmonary embolism (PE).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Hemodynamic instability with any of the following present:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will have their pulmonary embolism treated with anticoagulants alone. There will be no procedure for this group.
Drug: Anticoagulation
Subjects will have their pulmonary embolism treated with anticoagulants and mechanical aspiration thrombectomy with the Indigo® Aspiration System.
Device: mechanical aspiration thrombectomy
Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH)
Mechanical aspiration thrombectomy with the Indigo Aspiration System.
Also known as: Indigo Aspiration System
Change in RV/LV Ratio
Change in RV/LV ratio at 48 hours on original therapy as assessed by computed tomography pulmonary angiography (CTPA). Negative change values represent a reduction in the ratio of right ventricular to left ventricular diameter, consistent with improvement in right ventricular dilation.
Time frame: 48 hours post-randomization
Major Adverse Events
Major adverse events (MAEs) within 7 days: a composite of clinical deterioration requiring escalation of care, PE-related mortality, symptomatic recurrent PE, or major bleeding
Time frame: within 7 days post-randomization
Functional Outcome Assessment With the 6-minute Walk Test
Functional outcome as assessed by the 6-minute walk test (6MWT) through 90 days. The 6-minute walk test measures distance walked in meters, with longer distances being better.
Time frame: Through 90 days post-randomization
Functional Outcome Assessment With the New York Heart Association Classification
Functional outcome as assessed by the New York Heart Association classification (NYHA) through 90 days. The New York Heart Association classification ranges from Class I (no limitations) -IV (severe limitation), with higher classifications being worse.
Time frame: Through 90 days post-randomization
Functional Outcome Assessment With the Post Venous Thromboembolism Functional Status Scale
Functional outcome as assessed by the Post Venous Thromboembolism Functional Status (PVFS) scale through 90 days. The Post Venous Thromboembolism Functional Status scale ranges from 0-5, with higher scores being worse.
Time frame: Through 90 days post-randomization
Functional Outcome Assessment With the Modified Medical Research Council Dyspnea Scale
Functional outcome as assessed by the modified Medical Research Council Dyspnea Scale (mMRC) through 90 days. The modified Medical Research Council Dyspnea Scale ranges from 0-4, with higher scores being worse.
Time frame: Through 90 days post-randomization
Functional Outcome Assessment With the Borg Scale
Functional outcome as assessed by the Borg Scale through 90 days. The Borg Scale ranges from 0-10, with higher scores being worse.
Time frame: Through 90 days post-randomization
Quality of Life Assessment With the Pulmonary Embolism Quality of Life Questionnaire
Quality of Life (QoL), as assessed by the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QoL) through 90 days. The Pulmonary Embolism Quality of Life Questionnaire measures the percent of life affected by PE across 6 dimensions (including: Frequency of complaints, Limitations in activities of daily living (ADL), Work-related problems, Social limitations, Intensity of complaints, Emotional complaints), with higher scores being worse.
Time frame: Through 90 days post-randomization
Quality of Life Assessment With the EQ-5D-5L Questionnaire
Quality of Life (QoL), as assessed by the EQ-5D-5L Questionnaire through 90 days. The EQ-5D-5L index is a preference-weighted measure of health status derived from five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Index values represent overall health status, with higher scores indicating better health status. The Visual Analogue Scale (VAS) scale is part of the questionnaire and ranges from 0-100, with higher scores being better.
Time frame: Through 90 days post-randomization
All-cause Mortality
All-cause mortality within 90 days
Time frame: within 90 days post-randomization
PE-related Mortality
PE-related mortality within 90 days
Time frame: within 90 days post-randomization
Symptomatic PE Recurrence
Symptomatic PE recurrence within 90 days
Time frame: within 90 days post-randomization
| Milestone | Anticoagulation (AC) | Indigo |
|---|---|---|
| Started | 53 | 47 |
| Completed | 47 | 43 |
| Not completed | 6 | 4 |
Change in RV/LV ratio at 48 hours on original therapy as assessed by computed tomography pulmonary angiography (CTPA). Negative change values represent a reduction in the ratio of right ventricular to left ventricular diameter, consistent with improvement in right ventricular dilation.
| Change in RV/LV Ratio | Anticoagulation (AC) | Indigo |
|---|---|---|
| Change in RV/LV Ratio | -0.24 ± 0.40 | -0.52 ± 0.37 |
Major adverse events (MAEs) within 7 days: a composite of clinical deterioration requiring escalation of care, PE-related mortality, symptomatic recurrent PE, or major bleeding
| Participants | Anticoagulation (AC) | Indigo |
|---|---|---|
| Major Adverse Events | 4 | 2 |
Functional outcome as assessed by the 6-minute walk test (6MWT) through 90 days. The 6-minute walk test measures distance walked in meters, with longer distances being better.
| distance walked in meters | Anticoagulation (AC) | Indigo |
|---|---|---|
| Functional Outcome Assessment With the 6-minute Walk Test | 368.0 ± 127.78 | 478.7 ± 159.47 |
Functional outcome as assessed by the New York Heart Association classification (NYHA) through 90 days. The New York Heart Association classification ranges from Class I (no limitations) -IV (severe limitation), with higher classifications being worse.
| Participants | Anticoagulation (AC) | Indigo |
|---|---|---|
| Class IV | 1 | 0 |
| Class III | 2 | 1 |
| Class II | 8 | 0 |
| Class I | 34 | 37 |
Functional outcome as assessed by the Post Venous Thromboembolism Functional Status (PVFS) scale through 90 days. The Post Venous Thromboembolism Functional Status scale ranges from 0-5, with higher scores being worse.
| Participants | Anticoagulation (AC) | Indigo |
|---|---|---|
| Severe functional limitations | 3 | 1 |
| Moderate | 3 | 2 |
| Slight | 7 | 8 |
| Negligible | 8 | 5 |
| No functional limitations | 23 | 23 |
Functional outcome as assessed by the modified Medical Research Council Dyspnea Scale (mMRC) through 90 days. The modified Medical Research Council Dyspnea Scale ranges from 0-4, with higher scores being worse.
| score on a scale | Anticoagulation (AC) | Indigo |
|---|---|---|
| Functional Outcome Assessment With the Modified Medical Research Council Dyspnea Scale | 0.6 ± 0.95 | 0.4 ± 0.94 |
Functional outcome as assessed by the Borg Scale through 90 days. The Borg Scale ranges from 0-10, with higher scores being worse.
| score on a scale | Anticoagulation (AC) | Indigo |
|---|---|---|
| Functional Outcome Assessment With the Borg Scale | 0 (0.0 to 0.3) | 0 (0.0 to 0.5) |
Quality of Life (QoL), as assessed by the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QoL) through 90 days. The Pulmonary Embolism Quality of Life Questionnaire measures the percent of life affected by PE across 6 dimensions (including: Frequency of complaints, Limitations in activities of daily living (ADL), Work-related problems, Social limitations, Intensity of complaints, Emotional complaints), with higher scores being worse.
| percent of life affected by PE | Anticoagulation (AC) | Indigo |
|---|---|---|
| Quality of Life Assessment With the Pulmonary Embolism Quality of Life Questionnaire | 21.7 ± 22.0 | 15.8 ± 20.0 |
Quality of Life (QoL), as assessed by the EQ-5D-5L Questionnaire through 90 days. The EQ-5D-5L index is a preference-weighted measure of health status derived from five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Index values represent overall health status, with higher scores indicating better health status. The Visual Analogue Scale (VAS) scale is part of the questionnaire and ranges from 0-100, with higher scores being better.
| score on a scale | Anticoagulation (AC) | Indigo |
|---|---|---|
| Index | 0.811 ± 0.221 | 0.811 ± 0.236 |
| Visual Analog Scale | 77.9 ± 18.2 | 80.2 ± 14.9 |
All-cause mortality within 90 days
| Participants | Anticoagulation (AC) | Indigo |
|---|---|---|
| All-cause Mortality | 1 | 4 |
PE-related mortality within 90 days
| Participants | Anticoagulation (AC) | Indigo |
|---|---|---|
| PE-related Mortality | 0 | 2 |
Symptomatic PE recurrence within 90 days
| Participants | Anticoagulation (AC) | Indigo |
|---|---|---|
| Symptomatic PE Recurrence | 1 | 1 |
Collected over 90 days post-randomization. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anticoagulation (AC) | 1/53 (1.9%) | 14/53 (26.4%) | 5/53 (9.4%) |
| Indigo | 4/47 (8.5%) | 11/47 (23.4%) | 8/47 (17%) |
| Event | Anticoagulation (AC) | Indigo |
|---|---|---|
| HemoptysisRespiratory, thoracic and mediastinal disorders | 0/53 | 1/47 |
| Cardiac arrestCardiac disorders | 0/53 | 1/47 |
| Left radial artery bleedInjury, poisoning and procedural complications | 0/53 | 1/47 |
| New acute bilateral LE DVT and edemaVascular disorders | 0/53 | 1/47 |
| Adenocarcinoma of the gastroesophageal junctionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/53 | 1/47 |
| Anaphylactic ShockImmune system disorders | 0/53 | 1/47 |
| Trauma (due to multiple gunshot wounds head, face, groin, R hip, L buttock)Injury, poisoning and procedural complications | 0/53 | 1/47 |
| Severe TachycardiaCardiac disorders | 0/53 | 1/47 |
| Failure to thriveMetabolism and nutrition disorders | 0/53 | 1/47 |
| Recurrent Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/53 | 1/47 |
| Event | Anticoagulation (AC) | Indigo |
|---|---|---|
| HemoptysisRespiratory, thoracic and mediastinal disorders | 0/53 | 1/47 |
| Severe Allergic ReactionImmune system disorders | 0/53 | 1/47 |
| Perivascular LymphocyticSkin and subcutaneous tissue disorders | 0/53 | 1/47 |
| Chest pain and SOBGeneral disorders | 0/53 | 1/47 |
| Chest PainGeneral disorders | 0/53 | 1/47 |
| PneumoniaInfections and infestations | 0/53 | 1/47 |
| Duodenal UlcersGastrointestinal disorders | 0/53 | 1/47 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 0/53 | 1/47 |
| AKIRenal and urinary disorders | 1/53 | 0/47 |
| Worsening Urinary Tract InfectionInfections and infestations | 1/53 | 0/47 |
| Age, Continuous(years) | Anticoagulation (AC) | Indigo | Total |
|---|---|---|---|
| Mean | 61.2 ± 14.19 | 59.5 ± 13.22 | 60.4 ± 13.70 |
| Sex: Female, Male(Participants) | Anticoagulation (AC) | Indigo | Total |
|---|---|---|---|
| Female | 28 | 18 | 46 |
| Male | 25 | 29 | 54 |
| Race/Ethnicity, Customized(Participants) | Anticoagulation (AC) | Indigo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 |
| Not Hispanic or Latino | 49 | 37 | 86 |
| Unknown | 1 | 1 | 2 |
| Not Reported | 0 | 3 | 3 |
| Not collected due to local privacy regulations | 3 | 3 | 6 |
| Race/Ethnicity, Customized(Participants) | Anticoagulation (AC) | Indigo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 18 | 31 |
| White | 35 | 22 | 57 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 4 | 5 |
| Not collected due to local privacy regulations | 3 | 3 | 6 |
| Other | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2023 to primary completion in Jun 2025, 18 months.
Results were first posted in Aug 2026, 1 year 2 months after primary completion.
Of 150 interventional studies with no phase under Pulmonary Embolism, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.